Official Dragon Pharma announcements — third-party lab test results, new product launches, restock updates and peptide range releases. This section covers quality transparency reports, catalogue expansions and back-in-stock notifications for the Dragon Pharma range.
Dragon Pharma's News and Events section is the primary source for official announcements including: published third-party laboratory test results for specific products, new product launches across injectable, oral, peptide and SARM categories, restock updates for products returning after supply shortages, and range expansion announcements as new compounds are added to the catalogue.
When Dragon Pharma completes independent third-party laboratory testing and publishes results, the announcement appears here first. Published results confirm compound identity, concentration accuracy and purity for the specific batch tested — providing objective quality verification independent of manufacturer claims. Lab test announcements for Masteron 200 and Testosterone Enanthate 250 are available in this section.
Dragon Pharma announces that Masteron 200 and Testosterone Enanthate 250 have passed independent third-party laboratory testing. Masteron 200 returns to stock after global raw material shortage. Lab results confirm concentration accuracy and purity for both products.
Dragon Pharma November 2025 inventory update — new GHRP-2, GHRP-6, GHK-Cu 50mg, Klow and Glow peptide blends launched. Anavar, Superdrol, Enantat 250, Enantat 400, Cypionat 250, Cock Bombs, Levitra and Atorvastatin restocked.
Dragon Pharma November 2025 peptide launch — 13 new compounds across immune support, longevity, weight management, hormonal support, tissue repair and GH secretagogue categories. All third-party tested.
Dragon Pharma April 2025 — launch of Mazdutide, Survodutide and Retatrutide. Three next-generation metabolic peptides covering GLP-1/Glucagon dual agonism and GIP/GLP-1/Glucagon triple agonism for weight management and metabolic research.